-
As the baby boomers become older adults, we will see a rapid rise not only in the older population, but also an increase in older patients. While older adults accounted for 13% of the population in the year 2000, by 2030 they will be at least 20% of the population, or almost 71 million.
-
-
Rivaroxaban (Xarelto), Janssen Pharmaceutical's once-a-day oral Xa inhibitor, has been approved for reducing the risk of stroke in patients with atrial fibrillation.
-
-
An updated meta-analysis of birth defects in infants with first trimester efavirenz exposure was conducted and included published literature up until July 2011.
-
The toxicity associated with intestinal habitation by Clostridium difficile ranges from asymptomatic colonization to life-threatening infection. In the United States, C. difficile is the most common cause of health care-associated diarrhea.
-
A low-dose sublingual formulation of Zolpidem has been approved by the FDA for the management of middle-of-the-night (MOTN) awakening. Zolpidem, marketed as Ambien, was originally approved in 1992. The new formulation is marketed by Transcept Pharmaceuticals as Intermezzo.
-
The use of ambulatory blood pressure (BP)monitoring as a diagnostic strategy for the diagnosis of hypertension after finding an initial raised BP reading in the doctor's office would reduce misdiagnosis. The additional costs of ambulatory monitoring are counterbalanced by cost savings from better targeted therapy and, therefore, ambulatory monitoring is recommended for most patients before the start of antihypertensive drug therapy.
-
A post-stroke analysis of more than 20,000 patients in 35 countries showed that the lowest risk systolic blood pressure (BP) range is 130-139 mmHg. There is a J-shaped curve of risk with an increase in recurrent stroke among patients with a systolic BP below 120 mmHg and above 140 mmHg.
-
Behavioral therapy works as well as drug treatment for male overactive bladder.